Engaging Thought Leadership
Over 100 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
Discovery & Development Europe 2025
23 - 24 June 2025 | Basel, Switzerland
Pushing traditional boundaries in pharmaceutical science by accelerating the discovery & development of novel therapeutics
Discovery & Development Europe 2025
Meet Our Expert Speakers
Discovery & Development Europe 2025 again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.
Andreas Gryczke
Director, Process Engineering,
AbbVie
Banurekha Lakshmanan
Global Head of Data Office,
AstraZeneca
Emma Mead
Chief Scientific Officer, Oxford Drug Discovery Institute,
University of Oxford
Heinrich Haas
Chief Technology Officer,
Neovacs
Karin Conde-Knape
Senior Vice President Global Drug Discovery,
Novo Nordisk
Morten Grunnet
Vice President, Head of Neuroscience,
Lundbeck
Philippe Marc
Executive Director, Global Head of Integrated Data Sciences,
Novartis
Shadi Farhangrazi
Chief Executive Officer,
S.M. Discovery Group
Sorina Morar-Mitrica
Director Science &Technology,
Novartis
Stephen Pham
Senior Vice President, Product Development,
Avalyn Pharma Inc.
Ulrich Betz
Senior Vice President Innovation,
Merck
Vineeta Tripathi
Chief Executive Officer,
Vitarka Therapeutics
Aaron Smith
Associate Director,
AstraZeneca
Abhishek Choudhary
Principal Data Engineer,
Bayer
Abi Heath
Patent Attorney & Counsel,
Kilburn & Strode
Alain Martelli
External Science Lead Europe, Discovery Network,
Pfizer
Alexander Natz
Secretary General,
EUCOPE
Amal Ali Elkordy
Professor,
University of Sunderland
Amardeep Singh Bhalla
Executive Director,
Regeneron
Andreas Bernkop Schnurch
Professor,
University of Innsbruck
Andreea Apostol
Women in Leadership Strategy, Operations Lead (Diversity and Inclusion Council Europe),
Pfizer
Andrew Woodhead
Head of Chemistry,
Astex Pharmaceuticals
Andrew Ledgard
Senior Scientist,
Recursion
Andy Pike
Senior DMPK Discovery and Development Lead, Director,
AstraZeneca
Anna-Pia Papageorgiou
Policy Officer, Health Innovations & Ecosystems, DG Research & Innovation,
European Commission
Antonia Stepan
Section Head, Medicinal Chemistry,
Roche
Schedl_quantro-tx.jpg?length=600&name=1a7420d5-7d72-4600-b14a-ead67fd7791c-2-11764368speaker_photo-039_20220601_(c)Schedl_quantro-tx.jpg)
Arianna Sabò
Head of Research & Discovery,
QUANTRO Therapeutics
Arne Skerra
Professor,
Technische Universität München
Benedict Cross
CTO,
PhoreMost Ltd
Burkhard Schäfer
Managing Director & Director at SiLA,
SiLA
Christine Maurer
Scientific Associate Director Biotransformation,
Merck & Cie KmG
Christoph Rösli
Director Research,
CSL Behring & BaseLaunch
Chuang Kee Ong
Director Data Product,
GSK
.jpg?length=600&name=e73c85c3-43f1-4040-a19a-58133b2c8d0e-2-11764368speaker_photo-KITZ_vanTILBURG-Cornelis_180502_2988-(6).jpg)
Cornelis Van Tilburg
Head of KiTZ CTU,
Hopp-Kindertumorzentrum Heidelberg
Covadonga Paneda
Chief Operating Officer,
Altamira Therapeutics
Daniel Tondera
Head of Biology,
Pantherna Therapeutics
David Jenkinson
Head of Childhood Cancer Translational Challenge,
LifeArc
David Dexter
Research Director,
Parkinson's UK
David Gnutt
Vice President, Complex In Vitro Lead, RED Cardiovascular, Renal and Immunology,,
Bayer
Davide Gianni
Senior Director,
AstraZeneca
Delphine Heenen
Kicker In Chief Managing Director,
KickCancer
Diana Knapp-Bühle
Associate Director and DMPK Lead,
Merck Healthcare KGaA
Duane Schulthess
CEO,
Vital Transformation
Eric Lorent
Senior Scientist,
Sanofi
Estelle Beguin
Director of Technology Research,
Ethris
Eva Aparicio
Product Owner,
Roche
Fabrizio Dissegna
Formulator,
Chiesi
Farshad Ramazani
Senior Expert Science & Technology,
Novartis
Florian Ries
Senior Scientist,
AbbVie
Gergely Toth
Chief Executive Officer & Chief Scientific Officer,
Cantabio Pharmaceuticals
Giovanni Spagnolli
Chief Technology Officer,
Sibylla Biotech
Giovanni Ca'Zorzi
Strategic Communications,
Cohesion Bureau
Heena Khatter
Principal Scientist,
Roche
Heide Düvel
Scientific Associate Director DMPK,
Merck Healthcare KGaA
Hemachandran Kannan
Director of the AI Centre,
Woxsen University
Ian Roberts
Director of Therapeutic Technology,
Healx
Iris Valtingojer
Sanofi Childhood Cancer R&D CSR Lead,
Sanofi
Jack Doolan
Investigator,
GSK
James Dale
Director of Drug Discovery,
PharmEnable Therapeutics
James Love
Vice President, Automation and Process Optimization,
Novo Nordisk
James Connell
Scientific Director - Translational Matrix Group,
LifeArc
Jens Twellmeyer
Associate Director Science & Technology,
Novartis
Jitendra Kumar
Lead Scientist, Chemistry,
Entos Pharmaceuticals US Inc
Joao Seixas
CEO,
TargTex
Joel Richard
Executive Head of Product Development,
DBV
Johanna Roostalu
Director, Therapeutics, Venture Creation,
BioInnovation Institute
Jonathan Hopper
Vice President, Platforms & Founder,
OMass Therapeutics
Jörg Berghausen
Associate Director,
Novartis
Jose-Carlos Gomez-Tamayo
Scientist,
Janssen Pharmaceutical Companies of Johnson & Johnson
Kamalinder Kaur Singh
Professor of Pharmaceutical Technology and Drug Delivery,
University of Central Lancashire
Karsten Maeder
Professor,
Martin Luther University Halle-Wittenberg
Katja Petkau-Milroy
Formulation Scientist,
Microsol
Kelly Zalocusky
Senior Director of Computational Biology, Neuroscience,
Recursion Pharmaceuticals
Knut Biber
Research Fellow & Head of Glial Biology Team,
AbbVie
Konstantinos Gkatzis
Cardiovascular Team Lead & COO at Myrtil Biotechnologies,
Ksilink
Kristina Levan
Business Developer,
Business Region Gothenburg
Krisztian Kaszas
Sr Scientist, Assay Automation,
Johnson & Johnson
Lars van der Veen
Chief Scientific Officer,
ionctura
Laura Gasparini
Director -Tau pathobiology,
AbbVie
Lene Gerlach
Venture Partner, Founder of Women in Life Science Denmark (WiLD),
Hadean Ventures
Lubor Gaal
Chief Financial Officer & Chief Business Officer,
Circio
Maeve Caldwell
Professor in Neuroscience, Physiology,
Trinity College Dublin
Manuela Cerina
Scientific Director of Neurodegeneration,
LifeArc
.jpg?length=600&name=1331ca3f-d428-4603-8c2e-f580543806cd-2-11764368speaker_photo-E4E7916C-3A57-465C-93C7-31BC36FB8F34-(1).jpg)
Marcos Costa
Principal Scientist,
Roche
Maria Levitin
Director of RNA Oligonucleotide Delivery, Genetic Medicine,
Grünenthal GmbH
.jpg?length=600&name=bf0f9a64-4ef1-48c0-a59b-cf12aabf7598-2-11764368speaker_photo-20250203_102420-(1).jpg)
Marie-Christine Pardon
Assistant Professor in Translational Neuroscience,
University of Nottingham
Marius Lutz
Scientist, High-Throughput Experimentation, Chemical Reaction Screening,
Hoffmann La Roche Ltd
Mark Chiu
President & Chief Scientific Officer,
Tavotek BioTherapeutics
Markus Hierl
Principal Associate,
Hoffmann La Roche Ltd
Martinus Capelle
Scientific Director,
Johnson & Johnson
Meike Harms
Lead Scientist,
Merck
Meiling Li
Technical project leader,
Roche
Michael Johnson
Professor of Neurology and Genomic Medicine,
Imperial College London
Michele Cleary
President & Chief Scientific Officer,
Advancium Health Network
Miroslav Cik
Senior Principal Research Scientist,
Abbvie
Moein Moghimi
Professor of Nanomedicine and Pharmaceutics, School of Pharmacy,
Newcastle University
Naisha Shah
Vice President of Data Science,
BioAge Labs
Paulina Kolasinska-Zwierz
Principal Scientist,
Alchemab
Peng Leong
CBO and Head of Brain Aging,
Bioage labs
Phil Noble
Head of Single B Cell Antibody Discovery,
UCB Pharma
Philip Hewitt
Global Head of Early Investigative Toxicology,
Merck
Poppy Winlow
Senior Research Scientist,
AstraZeneca
Rainer Wilcken
Director, Computational Chemistry,
Flare Therapeutics Inc
Rajaa Sukhun
Senior Director of Research DMPK,
Cytokinetics
Ramesh Kashi Kashi
Senior Scientific Advisor,
EPOK Therapeutics
Rick Ewing
VP, Head of Chemistry,
Rapafusyn Pharmaceuticals
Robin Loving
Chief Scientific Officer,
Salipro Biotech AB
Roderick Beijersbergen
Head of NKI Genomics Core Facility & Professor of Functional Genomics,
The Netherlands Cancer Institute
Sabine Kuratli
CMC Lead,
CEPI
.jpg?length=600&name=5d9d5049-7369-4b94-97b4-06cd49798ce9-2-11764368speaker_photo-Sagar-pic-Image-(2).jpg)
Sagar Chandekar
Senior Medical Director, Alzheimer's Disease,
Novo Nordisk
Sam Daems
Portfolio Principal,
Waterland Private Equity
Sandor Batkai
Freelance Consultant,
Formerly Cardior Pharmaceuticals
Sarah Jolly
Principal Scientist,
LifeArc
Shayoni Dutta
Data Science Manager,
GSK
Shilpa Thosar
Former Director,
Cara Therapeutics
Shreenivasa Rajanala
VP, Global Head of Data Science and Advanced Analytics,
Bayer
Simone Vecchi
Associate Director - Drug Product Development Scientific Integrator,
Johnson & Johnson Innovative Medicine
Simone Hornemann
Director UZH CRISPR Screening Hub,
University of Zurich
Sonja Kühn
Head of Structural Biophysics and Computational Chemistry PA, Research,
Servier
Sophie Janbon
Director,
AstraZeneca
Steen Krogsgaard
Scientific Automation Director,
Novo Nordisk
Stefan Schiesser
Director of Medicinal Chemistry,
AstraZeneca
Stephanie Harlfinger
Senior Director, Global Head NCE DMPK,
Merck & Cie KmG
Supriyadi Hafiz
Senior Scientist,
Merck
Suruchi Vishwasrao
Senior Scientist,
Merck Life Science Pvt. Ltd.
Sven Verguts
Associate Director, Emerging Biotech & ATMPs,
Merck
Tamara Maes
Former Chief Scientific Officer & Founder,
Oryzon Genomics
Tanvir Tabish
Director, Early Formulation Development,
AstraZeneca
Thanneer Malai Perumal
Senior Principal Scientist,
Hoffmann La Roche Ltd
Thomas Von Erlach
Chief Scientific Officer,
Vivtex
Tjasa Vrlinic
Principal Investigator,
Medincell
Tom Kissling
pRED Automation Partner & Director at SiLA,
F. Hoffmann-La Roche AG
Tomasz Ratajczak
Formulation Expert,
Polpharma
Toria Legh-Land
Computational Pharmaceutics Lead,
Microsol
Trond Ulven
Professor,
Copenhagen University
Valentina Romeo
Principal Scientist & Group Leader,
Roche
Varun Kushwah
Principal Scientist,
RCPE
Vik Reebye
Head of Academic Partnerships,
MiNA Therapeutics Ltd
Virginia Ballotta
New Ventures Manager,
BaseLaunch
Vladimir Talibov
Associate Principal Scientist,
Sprint Bioscience
Yi Sun
Associate Professor,
Technical University of Denmark
Zeeshan Ahmad
Reader in Pharmaceutics and Drug Delivery,
University of Manchester
Zhi Yao
Principal Scientist,
LifeArc
Zhizhou Fang
Associate Scientific Director in vitro DMPK,
Merck Healthcare KGaA
Zoran Rankovic
Director of the Centre for Protein Degradation,
St Jude Children's Research Hospital
Meet Our Esteemed Sponsors
Platinum Sponsors
XtalPi
Platinum Sponsor
XtalPi is an innovative research platform company powered by artificial intelligence (AI) and robotics. Established in 2015 by three postdoctoral physicists at MIT, XtalPi is dedicated to driving intelligent and digital transformation in the life sciences and materials sciences sectors. XtalPi combines quantum physics, AI, cloud computing, and large-scale robotics to provide R&D solutions, services, and products for pharmaceuticals, biotechnology, renewable energy, and advanced materials industries globally.
XtalPi
Platinum Sponsor
XtalPi is an innovative research platform company powered by artificial intelligence (AI) and robotics. Established in 2015 by three postdoctoral physicists at MIT, XtalPi is dedicated to driving intelligent and digital transformation in the life sciences and materials sciences sectors. XtalPi combines quantum physics, AI, cloud computing, and large-scale robotics to provide R&D solutions, services, and products for pharmaceuticals, biotechnology, renewable energy, and advanced materials industries globally.
Gold Sponsors
BioDuro-Sundia
Gold Sponsor
BioDuro is a US company founded in 1996, and headquartered in Irvine, California. With more than 2,000+ scientists, we have 7 R&D and manufacturing campuses across the US and China. We offer fully integrated CRDMO services from discovery to commercial manufacturing across medicinal chemistry, biology, DMPK, drug substance and drug product, including multiple modalities small molecules, peptides, oligonucleotides and antibody drug conjugates. We leverage our broad capabilities and unique technology platforms to empower biotech and pharmaceutical partners worldwide. Our integrated approaches accelerate and de-risk new drug discovery and development, creating higher value outcomes for our clients. Committed to the highest standards of compliance and business operations, we maintain a science-driven, customer-oriented, innovative and people-focused culture. As a pure-play CRDMO, BioDuro operates under one global standard, providing integrated, fast, and flexible services to meet the unique needs of our clients and accelerate development timelines.
bit.bio
Gold Sponsor
bit.bio designs and manufactures human cells to advance drug discovery and biomedical research enabling transformative treatments in human health. Using our proprietary deterministic cell programming technology, opti-ox, we convert induced pluripotent stem cells (iPSCs) into any desired human cell type in a single step. Our AI powered discovery platform identifies unique combinations of transcription factors that can program any desired cell type with exceptional purity and consistency at scale, with products ready to ship globally. To date, bit.bio’s ioCells portfolio features 45 products, including ioWild Type Cells, ioDisease Model Cells, and ioCRISPR-Ready Cells. Since spinning out from the University of Cambridge and launching in 2016, we have raised approximately $225m from leading investors, including Arch Venture, Blueyard Capital, Charles River Laboratories, Foresite Capital, M&G, Milky Way, National Resilience, and Tencent.
Silver Sponsors
Alithea Genomics
Silver Sponsor
Alithea Genomics is a global leader in scalable transcriptomics solutions for screening applications. We work with pharma, biotech and agrochemical clients to boost and de-risk their compound selection efforts. Our high throughput and ultra-low cost library preparation technologies (DRUG-seq) enable RNA-seq data to be generated from several thousands samples in a convenient and streamlined solutions. Our pipeline does not require RNA extraction and has been validated on several cell lines and organoid types. On the data analysis side, we provide default upstream, downstream and QC analysis but we also provide bespoke solutions via our team of bioinformatic experts. In addition to library preparation, sequencing and data analysis, we provide end-to-end and very high-throughput cell culture, treatment and imaging services (cell painting).
Axxam
Silver Sponsor
Axxam provides integrated early discovery services and solutions across the life sciences industry. We support pharmaceutical and biotech companies, start-ups, patient foundations, and academic groups in their journey from target assessment to lead optimization across all therapeutic areas and target classes. Axxam’s services comprise assay development, hit identification, including high-throughput screening, and hit-to-lead activities.
BDD Pharma
Silver Sponsor
BDD is an integrated CDMO/CRO with over 25 years experience in drug delivery, GMP manufacture, and early clinical testing. Our formulation capabilities span from simple capsule/tablet dosage forms for rapid clinical evaluation to complex modified-release profiles using techniques like hot melt extrusion and our proprietary technologies – OralogiK™ and CologiK™. OralogiK™ is a timed-release platform that can deliver drugs, or combinations of drugs, at predetermined times post-dosing, enabling the most complex profiles to be achieved. CologiK™ is an extension of the OralogiK™ platform that enables delivery of APIs to the colon for localised treatments or to avoid release in the stomach or small intestine. Both technologies have been proven clinically with a range of different APIs, from small molecules to biologics. BDD’s product design strategies are underpinned by our unique understanding of biopharmaceutics, gained through years of clinical visualisation of product performance in humans using our Gamma Scintigraphic imaging capabilities. Through our Lean Clinical Development™ pathway, we streamline the traditional early clinical development approach. We combine formulation development with “just in time” small scale clinical manufacturing, and Phase 1 testing to provide our clients with the fastest path to Phase 1 clinical data.
ChemAxon
Silver Sponsor
Chemaxon is a leading cheminformatics company providing software solutions for property calculation and molecule design, chemical drawing, chemical search and compound data management. Certara acquired Chemaxon in 2024 to close gaps in the design-make-test-analyze cycle, bring promising leads into biosimulation, and speed up the launch of new medicines. Together we help you innovate with confidence by turning your discovery process into a competitive advantage. • Chemaxon’s universal chemical drawing tool serves the needs of research scientists and gives them access to our industry-standard chemical intelligence. • Our solutions support the creation of new molecule design ideas and enable medicinal chemists to utilize advanced computational techniques and visualize their data. • We support the standardization of chemical information to improve the quality of training data for AI models and scale your search to the range of hundreds of millions – billions of chemical structures.
HUB Organoids
Silver Sponsor
HUB Organoids BV is a pioneering biotechnology company specializing in the application of Organoid Technology to drug discovery, personalized medicine, and disease modeling. Founded in 2013 following the discovery of adult stem cells, HUB´s drug development platform uses advanced 3D organoid models derived from patient tissues, enabling more accurate and predictive research for preclinical testing and therapeutic development. HUB´s innovative platform accelerates the discovery of effective treatments by closely mimicking human biology and is available on a fee for service basis to scientists working in drug discovery and development in the therapeutic areas of oncology, inflammation/IBD, infectious diseases, and for toxicology investigation. HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany
IRBM
Silver Sponsor
IRBM is a scientific contract research organization (CRO) that stands at the forefront of drug discovery, leveraging a single, unified research facility to accelerate team-based breakthroughs and improve efficiencies from concept to candidate. With a history of contributing to several approved drugs, and its own internal pipeline of oncology and other therapeutic assets, IRBM is powered by deep collaborations and decades of expertise from leading global institutions. Their comprehensive in-house capabilities assist partners in achieving key milestones and progressing towards clinical readiness, positioning IRBM as a major player in driving innovation in the pharmaceutical and biotech fields. For further information, please contact us: bd@irbm.com Website: https://www.irbm.com/
NanoFCM
Silver Sponsor
NanoFCM provides a versatile and powerful platform - Flow NanoAnalyzer for the multiparameter analysis of functional nanoparticles (7-500 nm) at single-particle level which has the capacity to measure the size, concentration, and biological properties of nanoparticles. To our knowledge, Flow NanoAnalyzer is the only flow cytometry instrument that covers the size range of exosomes (30-120 nm). Flow NanoAnalyzer is expected to become a powerful tool for life science, nanoscience and nanotechnology studies. Flow NanoAnalyzer can be used for the characterization of extracellular vesicles(EVs), viruses, bacteria, and other natural biological nanoparticles as well as functional nanoparticles, which opens up a window to the nano-world for flow technology. By means of high-selectivity, high-resolution and high-throughput detection of the particle size, concentration, and biochemical properties of a single nanoparticles (7-1000 nm).
Nuvisan ICB GmbH
Silver Sponsor
Your partner of choice in bringing therapeutics to life
Nuvisan is a full-service contract research organisation (CRO) and development and manufacturing organisation (CDMO) with state-of-the-art laboratories in Germany and France.
Our pharmaceutical, biotechnology, venture capital and non-profit clients partner with us because our high-quality end-to-end solutions and scientific expertise enable us to streamline and accelerate drug discovery and development – from ensuring target understanding to helping bring therapeutics to life.
Founded over 40 years ago by a team of pharma industry innovators, Nuvisan has established a reputation for expertise and professionalism. Our team leaders have extensive experience in the biopharma industry, and our unique centres of excellence – for drug discovery in Berlin, formulation and GMP manufacturing in Sophia Antipolis, and our bioanalysis hub in Neu-Ulm – enable our experienced scientists to help guide and advance projects. We know how to discover, develop and bring the next generation of medicines to market. At the same time, we are committed to flexibility, transparency and collaboration in our approach, working closely with you to adapt to your individual needs, minimise risks and help deliver your project.
Pfanstiehl GmbH
Silver Sponsor
Pfanstiehl Inc. is a cGMP Manufacturer of High Purity Low Endotoxin components such as Trehalose, Sucrose, Mannitol, Maltose, Galactose (non-animal), Mannose, Tris base and Tris HCl and Amino Acids such as L-Arginine.L-Methionine and Histidine for Biologics, Biosimilars, Vaccines, Cell Culture Media and Injectables (liquid & lyo) located in Waukegan Illinois USA. Pfanstiehl has been in operation since 1919, focusing on both Biopharmaceutical excipients / critical components & Pharmaceutical HPAPIs / APIs (generic and on contract manufacturing base). Pfanstiehl specializes in isolation, purification, custom synthesis and scale-up development of regulated, high purity and low endotoxin Injectable Formulation Ingredients, Pharmaceutical Intermediates and Active Pharmaceutical Ingredients, in gram to multi-ton commercial quantities.
Schrodinger
Silver Sponsor
Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger’s software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs and is advancing three clinical-stage oncology programs. Founded in 1990, Schrödinger has approximately 900 employees operating from 15 locations globally. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com.
Symeres
Silver Sponsor
Symeres is the leading mid-sized transatlantic Contract Research Organization for your drug discovery and development challenges. With over 600 highly educated scientists in six locations in Europe and two in the USA, we offer best-in-class solutions for drug discovery and drug development, from small to medium-sized molecule hits. We are large enough to matter, and small enough to care. Our services span across early stage hit finding all the way to the delivery of your early clinical drug substance API.
Bronze Sponsors
Captisol
Bronze Sponsor
Captisol is a derivatized beta cyclodextrin used in 16 FDA-approved products to date, including VEKLURY® (remdesivir) and KYPROLIS®️ (carfilzomib) to help solubilize & stabilize difficult to deliver molecules. Made by CyDex Pharmaceuticals (a Ligand Company), Captisol is the leading pharmaceutical-grade sulfobutylether beta-cyclodextrin (SBECD), with an excellent record of safety and consistency.
Cell Signaling Technology
Bronze Sponsor
Doing good science is important. So is just doing good. Cell Signaling Technology (CST) is a different kind of life science company—one founded, owned, and led by active research scientists, with the highest standards of product and service quality, technological innovation, and scientific rigor for over 20 years. We consistently provide fellow scientists around the globe with best-in-class products and services to fuel their quests for discovery. Founded in 1999 and headquartered in Danvers, Massachusetts, USA, CST employs over 600 people worldwide. Helping researchers find new solutions is our main mission every day—but it’s not our only mission. We’re also dedicated to helping identify solutions to other problems facing our world. We believe that all businesses must be responsible and work in partnership with local communities, while seeking to minimize their environmental impact. That’s why we joined 1% for the Planet as its first life science member, and have committed to achieving net-zero emissions by 2029. At CST, we believe in the power and promise of science to solve the challenges we face as a global community. We’re a company of caring people driven by a devotion to facilitating good science—a company committed to doing the right thing for our Customers, our communities, and our planet.
.jpg?length=600&name=3d0c22d6-b4ef-4e05-be3b-05fbfbf42619-2-5668375logo-CDDV_L_BLUE_ON_BLUE_SHAD_CMYK-(10).jpg)
InnoCore Pharmaceuticals
Bronze Sponsor
InnoCore Pharmaceuticals is a biopharmaceutical drug delivery company specialized in the development of long acting and minimally invasive drug delivery products for the treatment of several (chronic) diseases e.g. oncology, pain, atherosclerosis, macular degeneration, CV, osteoarthritis. Our company is using a biodegradable polymer based platform for complex injectables by making microspheres, in-situ-forming depo's and implant formulations. We support the formulation of small molecules, peptides and proteins (including antibodies) for controlled release delivery from days up to six months.
Thermo Fisher Scientific
Bronze Sponsor
We enable life scientists to unlock the mysteries of biological complexity with cryo-electron microscopy (Cryo-EM). This invaluable technique provides structural insights for a wide range of intractable targets and has become integral to structure-based design. By enabling structure determinations of proteins and macromolecular complexes in near native states and the characterization of drug delivery systems, cryo-EM provides insights benefitting all stages in drug discovery from target evaluation through process development.
Network & Programme Sponsors
Almac
Network & Programme Sponsor
Operating from state-of-the-art facilities in the UK, US and Europe, Almac Pharma Services is a fully regulatory approved CDMO partnering with global pharmaceutical and biotechnology industries. With over 55 years' experience, we provide a comprehensive range of tailored solutions and access to a wealth of technical experts to support the delivery of your complex projects. Almac’s integrated pharmaceutical development solutions are tailored to meet your needs. Our scientists can develop your clinical candidate into an optimum formulation and manufacture oral dose products for all stages of clinical trials. We specialise in the manufacture & primary packaging of oral dosage forms as well as customised secondary packaging for all drug products including ultra-low temperature drug products. Almac works in close partnership with our clients offering unique solutions designed to support the efficient and successful development, and commercialisation of new treatment options.
Ardigen S.A
Network & Programme Sponsor
Ardigen is a leading AI Contract Research Organisation (CRO) dedicated to increasing the success rate of drug discovery. Recognized among the top 5% of AI in drug discovery companies worldwide, Ardigen integrates expertise in biology, bioinformatics, machine learning, and software engineering to deliver advanced computational solutions exclusively tailored for the biotechnology and pharmaceutical sectors. Over the past 10 years, we have earned the trust of over 120 clients, including 15 major pharmaceutical companies, by providing exceptional in silico research and data engineering services.
Aseptic Technologies
Network & Programme Sponsor
Aseptic Technologies, part of the SKAN Group, is a global leader in aseptic processing solutions, ensuring the highest sterility standards for pharmaceutical, biotech, and healthcare applications. We specialize in advanced fill and finish systems and isolator technologies. As a trusted partner to pharmaceutical manufacturers, we integrate aseptic processes from R&D to production, offering cutting-edge filling equipment, barrier technologies, and custom single use solutions to enhance efficiency and safety. With decades of expertise, we provide tailored solutions for parenteral drugs, ATMPs, and high-potency compounds. Our mission is to drive aseptic manufacturing excellence through innovation, customer-centric solutions, and industry-leading standards.
BrainXell
Network & Programme Sponsor
BrainXell provides high-purity, iPSC-derived human neurons and glia for research and development. Utilizing proprietary technology, we generate high-purity, subtype-specific neurons that mature rapidly and are ready for a variety of assays. Multiple neuron subtypes are available from control lines and can be made in custom batches from 50 million to 10 billion neurons from unique iPSC lines.
.jpg?length=600&name=c8f3ee46-970d-4da4-984f-fe6394fe9ac0-2-5668375logo-Glatt_PS_Mailchimp-header_schmaler-(1).jpg)
Glatt Pharmaceutical Services
Network & Programme Sponsor
Glatt Pharmaceutical Services supports pharmaceutical and biotech companies through every stage of drug product development, from initial formulation design to large-scale commercial manufacturing. With expertise spanning early-stage development, including preclinical and clinical supply production, Glatt ensures seamless scalability while maintaining stringent quality standards. Leveraging advanced technologies like fluidized bed systems, spray granulation, and Wurster coating, Glatt specializes in creating tailored solutions for solubility enhancement, modified release, and other complex drug delivery challenges. Partnering with Glatt means access to end-to-end solutions designed to streamline the path from innovation to market.
InProcess-LSP
Network & Programme Sponsor
InProcess-LSP: Innovators in Process Analytical Technology Founded in 2014 and headquartered in Oss, the Netherlands, InProcess-LSP has positioned itself as a leading innovator in the field of Process Analytical Technology (PAT). Central to the company’s success is the NanoFlowSizer, a pioneering technology developed to address the complex challenges of nanoparticle characterization in dynamic systems. The NanoFlowSizer represents a significant advancement in nanoparticle measurement, utilizing a non-invasive optical approach for real-time size characterization. This unique instrumentation enables continuous, in-flow analysis of turbid nanosuspensions with unprecedented speed and accuracy, eliminating the need for sample preparation. Its ability to measure particle size and size distribution in highly concentrated and dynamic systems sets it apart in the field of nanoparticle analysis.
Nikon Europe B.V
Network & Programme Sponsor
Nikon BioImaging Labs provide contract research services for microscope-based imaging and analysis to the biotech, pharma, and larger research communities. Each lab's full-service capabilities include access to cutting-edge microscopy instrumentation and software, but also the services of expert biologists and microscopists, who are available to provide quality cell culture, sample preparation, data acquisition, and data analysis services. Hamamatsu Photonics products and technology include optical sensors, light sources, and systems that use these components. They are applied to various new technologies and devices to support people’s lives and help realize a more comfortable and prosperous society. Hamamatsu products are widely used for state-of-the-art medical equipment, test and inspection systems, microscopes that reveal the functions of cells, and giant telescopes that explore the mysteries of the universe.
Onyx Scientific Limited
Network & Programme Sponsor
Onyx Scientific is the CDMO division of Ipca Laboratories, offering small molecule drug substance development and manufacturing services. Our MHRA-licensed sites in the UK offer early development of candidate APIs and manufacturing for clinical phases through to commercial supply. Dedicated solid-state and analytical chemistry teams expedite development activities at Onyx but are also available to provide full-service outsourced projects to complement or support your in-house campaigns. With a wealth of early development experience and success, our pragmatic, fit-for-purpose approach focuses on rapid process development and a view to future GMP campaigns. Where required, scale-up through Phase II towards commercial manufacture is retained either at Onyx or within the Group through transfer to our sister sites and colleagues in the USA and India.
Seppic S.A. - Établissement de Paris
Network & Programme Sponsor
Subsidiary of the Air Liquide Group since 1986, company of Air Liquide Healthcare, Seppic develops, manufactures and markets unique ingredients for cosmetic, nutraceutical, pharmaceutical, veterinary and industrial products. As expert in surfactants, polymers and formulation, Seppic offers pharmaceutical excipients adapted to oral, topical and parenteral routes of administration. Seppic’s parenteral excipients portfolio includes MONTANE™ PPI, a range of emulsifiers, and MONTANOX™ PPI, a range of solubilizers, providing formulators with high quality surfactants to ensure the most stable injectable formulations. Last year we launched MontanoxTM 20 HPB, our new non-ionic polysorbate with an improved formula dedicated to biological applications. Seppic surfactants comply with Good Manufacturing Practices (GMP Part II) and the current most important pharmacopoeias in the world (EP, USP-NF, JP/JPE and ChP), helping target multiple markets with one single range.
Start-Ups
SynSilico B.V
Start Up Zone
InnoSyn offers a team of passionate & experienced problem solvers, applying innovative and cost-efficient technologies such as flow chemistry, bio- and chemocatalysis, to advance competitiveness of our customers across the (fine) chemical industries. Whether you are looking for i. a scalable route to produce your new chemical compound of interest, or ii. facing challenges on your cost of goods of your current products, or iii. looking for manufacturing capacity for your specific chemical product or enzyme, InnoSyn can deliver you the unique value creating solution based on our over 25 years of experience.
Leveraging Advanced Screening Practices to Improve the Efficiency & Efficacy of Drug Discovery
Catch Up With Industry Experts on Drug Screening Strategies
BiomedGPT: Adopting a Generalist Approach to Biomedical AI
BiomedGPT, a versatile AI tool used for biomedical research demonstrated impressive results across a wide range of healthcare tasks.
The Application of RNAi Therapeutics for Cardiovascular Disease Treatment
Alnylam Pharmaceuticals explores the possibility of treating cardiovascular disease with RNAi therapeutics.
Goserelin Acetate – VitalDose® EVA Implant
AI/ML Advancements in Drug Formulation – The Potential of Self-Driving Labs
Intrepid Labs demonstrates how its self-driving lab uses ML and robotics to advance drug formulation.
2024 Nobel Prize in Chemistry Awarded to Pioneering Advances in Protein Design and Structure Prediction
The 2024 Nobel Prize in Chemistry was awarded to three scientists working on computational protein design and protein structure prediction.
Congress Center Basel
Messeplatz 21, CH-4058 Basel
By Rail
Basel is an international rail hub with direct ICE, IC and EC connections to Germany, Austria, Italy, France and the Benelux countries. Messe Basel can be reached in five to ten minutes from the three railway stations in Basel: SBB (Switzerland), SNCF (France) (Frankreich) and DB (Badischer Bahnhof, Germany)
By Tram
From the SBB/SNCF railway station, it’s a ten-minute journey on the No. 1 or 2 Tram to the “Messeplatz/Exhibition Square” stop where Messe Basel and the Congress Center are located. From Badischer Bahnhof railway station, “Messeplatz/Exhibition Square” is the second stop on the No. 2 or 6 tram.
By Air
EuroAirport Basel-Mulhouse-Freiburg is 15 minutes by car from Messe Basel. Basel municipal transport’s No. 50 bus additionally provides a straightforward connection from the airport to the SBB/SNCF railway station. From there, tram No. 1 or 2 will take you directly to Messeplatz/Exhibition Square. From Zurich Airport a direct rail connection will bring you to the SBB/SNCF railway station in Basel in less than an hour. For further information including a map and full directions, please visit: https://www.messe-basel.com/en/about-us/getting-to-messe-basel/
By Car
Basel is located at the point where the Swiss, German and French motorway networks all meet. The exhibition and congress site has its own direct link to the A2 motorway. The “Messe” exit will take you straight to the Messe Basel car park with its 1,200 parking spaces.
Oxford Global has secured a number of bedrooms at the Basel Marriott Hotel at a reduced conference rate:
- Sunday 22nd June 2025 – £265 (Including Breakfast & City Tax)
- Monday 23rd June 2025 – £265 (Including Breakfast & City Tax)
*Please note: £30 supplement is applicable for double occupancy
Should you wish to book a room, please visit our shop here.
Additionally, we kindly remind all attendees to only book their accommodation if they are registered for the event. This ensures that accommodations are available for those who have officially secured their attendance.
The final cut-off date to book bedrooms is Monday 2nd June 2025 – any bookings after this date are subject to availability and rates. Please note that any cancellations within 14 days prior to arrival are subject to full cancellation charges.
We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.
As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.
Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.
Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.
If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Discovery & Development Europe 2025 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.
